Group items tagged

Market Overview: Skin substitutes are natural, synthetic or biosynthetic materials, used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provides temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Skin substitutes provide a permanent solution and are used in the treatment of conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible. Market Dynamics: Rising chronic skin diseases is expected to drive the skin substitutes market. For instance, according to the global burden of disease study 2013, Skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases is increasing the demand for skin substitutes in the forecast period. Rising prevalence of diabetes is expected to boost the market. This is owing to the risk of developing a diabetic foot ulcer over the period of time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes related complications are expected to increase over the forecast period. There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Market Segmentation: Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

The Global Diabetic Foot Ulcer Market was valued at $4.48 billion in 2018 and is anticipated to exhibit 11.34% CAGR from 2019 to 2026, reaching $ XX billion by 2026.

Companion animals are domesticated or domestic-bred animals whose physical, emotional, behavioral and social needs can be readily met as companions in the home or a close daily relationship with humans. Companion animal health market mainly comprises of medicines, medicinal feed additives, and vaccines and caters to both foods producing and companion animals. China Companion Animal Health Market was worth US$ XX Million in 2019 and is expected to reach US$ XX Million by 2026, at a CAGR of XX% during the forecast period 2019-2026. Download Free Sample Report: https://www.datamintelligence.com/download-sample/china-companion-animal-health-market View Full Report Sample: https://www.datamintelligence.com/research-report/china-companion-animal-health-market

The global biopharmaceuticals market is set to exhibit a CAGR of 7.83% during 2019-2026 and is estimated to reach a market value of US $ XX billion by 2026. Biopharmaceuticals are large and complex molecular drugs that are mainly obtained from proteins and nucleic acids of living organisms such as microorganisms and animal cells also known as transgenic organisms. These drugs are obtained using biotechnology and have high-therapeutic value. Biopharmaceuticals are also known as biologics and biotech drugs and are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than the conventional small molecule drugs. Biopharmaceuticals are an alternative to the previously less effective and sometimes unsafe treatments and offer several benefits. Biopharmaceuticals benefits include highly effective and potent action, fewer side effects, can be tailored according to specific medical requirements of patients and they hold the potential to actually cure diseases at the root level. Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade and have changed the treatment of several chronic diseases, such as diabetes and cardiovascular diseases. Download free Report Sample: https://www.datamintelligence.com/download-sample/biopharmaceuticals-market View Full Report Sample: https://www.datamintelligence.com/research-report/biopharmaceuticals-market

Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production. The global chronic immune thrombocytopenia market size was worth $ XX billion in 2019 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026). View Full Report Sample: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market Download free Report Sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market